Bcell Design at MEDICA 2024: setting a new standard for diagnostic precision

Bcell Design will make a mark at MEDICA 2024, showcasing its advanced human Fc monoclonal antibodies designed specifically for in vitro diagnostics (IVD). Our antibodies are engineered to provide precision and reliability – a critical combination for laboratories and healthcare providers focused on improving diagnostic accuracy.

 

Why Bcell Design matters to diagnostics

Bcell Design’s monoclonal antibodies are not just another product on the market. They’re specifically designed to handle a wide range of diagnostic tasks, from early disease detection and biomarker identification to monitoring chronic conditions and pathogen detection. Their antibodies are validated across multiple platforms like DiaSorin LIAISON XL, BioMérieux Vidas, and bioVendor KleeYa, ensuring consistent performance across different diagnostic settings.

In an industry where accuracy is everything, these antibodies bring unmatched consistency to diagnostic assays like ELISA, immunoassays, and lateral flow tests. Laboratories that integrate Bcell Design’s antibodies into their systems report more reliable results, better lot-to-lot consistency, and fewer supply chain issues.

Antibodies that meet real-world needs

Bcell Design’s antibodies are designed to replace disease state plasma, offering a reliable alternative that eliminates ethical concerns and supply chain disruptions. They serve as positive controls and calibrators in IVD kits, guaranteeing consistent signal generation across different batches. This consistency is essential for companies that need to ensure their diagnostic platforms maintain high accuracy, without the risk of revalidating tests for each batch.

They are ISO 9001-certified and compliant with both IVDR and FDA standards, meaning you can trust them to meet the regulatory requirements of today’s stringent IVD landscape.

Quality control that saves time and resources

For labs looking to streamline their processes, Bcell Design’s antibodies offer a clear advantage. No matter which platform you’re using—ELISA, CLIA, LFIA, or DOTS—these antibodies help ensure antigen absorption and assay performance are consistent, reducing the need for time-consuming revalidations. This leads to faster testing, fewer errors, and lower operational costs.

External quality control you can count on

Bcell Design’s antibodies are not only used in-house but are also part of several external quality control programs. This means they’ve been tested and proven to perform in real-world diagnostic scenarios, ensuring reliable results across various types of immunoassays. If you’re looking for antibodies that you can trust in quality control settings, Bcell Design’s solutions are already recognized as some of the best in the industry.

 

Visit Bcell Design at MEDICA 2024

Bcell Design will be at Hall 3, Stand H56-1 at MEDICA 2024, ready to show you how their human Fc monoclonal antibodies can improve your diagnostic processes. Whether you’re looking for better accuracy, more reliable controls, or solutions that comply with global standards, Bcell Design offers antibodies that make a measurable difference.

How can we help?

General enquiry
Request a free sample
Custom development services
Technical support